German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

Nast, Alexander; Altenburg, Andreas; Augustin, Matthias; Boehncke, Wolf‐Henning; Härle, Peter; Klaus, Joachim; Koza, Joachim; Mrowietz, Ulrich; Ockenfels, Hans-Michael; Philipp, Sandra; Reich, Kristian; Rosenbach, Thomas; Schlaeger, Martin; Schmid-Ott, ­Gerhard; Sebastian, Michael; Kiedrowski, Ralph von; Weberschock, Tobias; Dressler, Corinna

doi:10.1111/ddg.14508

Cited by 48 publications

(85 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, patients in this study were severely affected in their PASI and DLQI scores, owing to the fact that the analysis was not based on a population sample, but included only patients starting systemic treatment with an IL17‐ or IL23‐blocker. This type of treatment is restricted to patients with moderate to severe psoriasis as defined by a PASI and DLQI score >10 or by the involvement of easily visible or sensitive areas of the body resulting in a severe reduction of quality of life (DLQI > 10) 28 . Accordingly, smoking, which is a well‐established risk factor for psoriasis, was somewhat more common in this sample compared to population studies 29 .…”

Section: Discussionmentioning

confidence: 92%

A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice

Hölsken

Krefting

Schneider

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory disease causing erythematous, scaly skin patches that are often itchy and painful. With a prevalence of around 2% in Western populations, it is among the most widespread skin conditions. 1,2 The pathological mechanisms are relatively well understood and effective systemic treatments to reduce skin symptoms have been developed. 3,4 However, a huge portion of psoriasis patients suffer from psychological comorbidities, foremost depressive symptoms. 5,6 Several factors are thought to underlie this connection between psoriasis and depression. On the one hand, the disabling symptoms have a significant impact on patients' quality of life and the easily visible plaques may lead to stigmatization and social withdrawal. 7 On the other hand, there is growing evidence that the peripheral systemic inflammation associated with psoriasis may facilitate the development of depression as well. 8

show abstract

Section: Discussionmentioning

confidence: 92%

A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice

Hölsken

Krefting

Schneider

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Therapeutic options for nail psoriasis include topical, intralesional, systemic agents, and laser treatment. The choice of treatments depends on multiple factors, including the age, the burden of the disease, accompanying diseases, individual preferences, and the risks of treatment [19][20][21]. For example, the possible side effects of oral treatment outweigh the clinical benefits in patients with mild, isolated nail disease.…”

Section: Discussionmentioning

confidence: 99%

Comparison of fractional laser‐assisted drug delivery and intralesional injection of triamcinolone acetonide in nail psoriasis

Nassar

Atef

Eldeeb

et al. 2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Background and objectives: The treatment of nail psoriasis is often unsatisfactory due to poor penetration of topical therapeutics through the nail plate. The development of innovative methods that provide adequate delivery of the drug into the nail is warranted. In this study, we aim to compare the efficacy of intralesional corticosteroid injection versus its topical application after fractional CO 2 laser in the treatment of fingernail psoriasis. Patients and Methods:The study included 36 patients with fingernail psoriasis divided into two groups. The nails in group A were treated with intralesional injection of triamcinolone acetonide while the nails in group B received fractional CO 2 laser therapy followed by topical application of the drug for six sessions. The evaluation was performed using NAPSI and dermatoscopic scores.Results: Both modalities yielded a significant improvement of the nail matrix and bed psoriatic signs. No statistically significant difference was found between the two groups by both clinical and dermatoscopic assessment. The laser treatment was associated with significantly lower pain scores (P = 0.03) and higher patient satisfaction (P = 0.007). Conclusions:Fractional CO 2 laser-assisted delivery of topical corticosteroids can be a potentially effective and well-tolerated therapeutic modality in the treatment of nail psoriasis with comparable efficacy to intralesional injection.

show abstract

“…There are well-defined guidelines for the treatment of psoriasis ( 67 , 68 ). The following drugs are FDA or EMA approved for psoriasis and/or psoriatic arthritis: TNFα inhibitors etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab; IL-17a inhibitors secukinumab and ixekizumab; IL-17A and IL-17F dual inhibitor bimekizumab; IL-17 receptor A/C inhibitor brodalumab; IL-12 and IL-23 inhibitor, ustekinumab; and IL-23 inhibitors guselkumab, tildrakizumab, and risankizumab ( 69 – 72 ).…”

Section: Chronic Inflammatory Skin Diseasesmentioning

confidence: 99%

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

et al. 2022

View full text Add to dashboard Cite

An estimated 20–25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.

show abstract

German S3‐Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – Part 1: Treatment goals and treatment recommendations

Cited by 48 publications

References 21 publications

A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice

A brief screening tool for depression in psoriasis patients: The Two Questions Test in clinical practice

Comparison of fractional laser‐assisted drug delivery and intralesional injection of triamcinolone acetonide in nail psoriasis

Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases

Contact Info

Product

Resources

About